Truvian
Total Raised
$224.1MInvestors Count
17Funding, Valuation & Revenue
7 Fundings
Truvian has raised $224.1M over 7 rounds.
Truvian's latest funding round was a Series D for $74M on July 17, 2024.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
7/17/2024 | Series D | $74M | 6 | |||
2/24/2021 | Series C | |||||
4/28/2020 | Loan | |||||
11/20/2019 | Series B | |||||
1/1/2018 | Series A |
Date | 7/17/2024 | 2/24/2021 | 4/28/2020 | 11/20/2019 | 1/1/2018 |
|---|---|---|---|---|---|
Round | Series D | Series C | Loan | Series B | Series A |
Amount | $74M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 6 |
Truvian Investors
17 Investors
Truvian has 17 investors. DNS Capital invested in Truvian's Series D funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
11/20/2019 | 7/17/2024 | 3 Series B, Series C (2021), Series D (2024) | Holding Company | Illinois | ||
11/20/2019 | 7/17/2024 | 2 Series B, Series D (2024) | Venture Capital | California | ||
2/24/2021 | 7/17/2024 | 2 Series C, Series D (2024) | Venture Capital | Canada | ||
Private Equity | Delaware | |||||
Venture Capital | Illinois |
First funding | 11/20/2019 | 11/20/2019 | 2/24/2021 | ||
|---|---|---|---|---|---|
Last Funding | 7/17/2024 | 7/17/2024 | 7/17/2024 | ||
Investor | |||||
Rounds | 3 Series B, Series C (2021), Series D (2024) | 2 Series B, Series D (2024) | 2 Series C, Series D (2024) | ||
Board Seats | |||||
Type | Holding Company | Venture Capital | Venture Capital | Private Equity | Venture Capital |
Location | Illinois | California | Canada | Delaware | Illinois |
Compare Truvian to Competitors
PixCell focuses on portable point-of-care blood diagnostics within the healthcare technology sector. The company has a platform called HemoScreen, which provides complete blood count (CBC) analyses with a 5-part differential for use in clinical settings, including primary care, emergency, oncology, and military. The HemoScreen employs microfluidics, lab-on-a-cartridge, and artificial intelligence to provide blood test results. It was founded in 2009 and is based in Yokneam, Israel. PixCell operates as a subsidiary of Soulbrain.
OncoHost provides solutions in precision oncology within the healthcare sector. The company's main offering is the PROphet platform, which utilizes bioinformatic proteomic pattern recognition and artificial intelligence (AI) to generate a personalized score that predicts the benefit of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, aiding in clinical decision-making. It was founded in 2017 and is based in Binyamina, Israel.
Founded in 2004, PinPointe USA, Inc. is a privately held, emerging medical technology with headquarters in Chico, California.
RedcellAI analyzes routine blood test data such as complete blood count (CBC) and familial chylomicronemia syndrome (FCS) using artificial intelligence to detect anomalies and generate clinical reports. The platform integrates with electronic medical records (EMRs) and insurance platforms. It was founded in 2025 and is based in Seoul, South Korea.
EFA Technologies focuses on the development of portable hematology labs within the healthcare sector. Their flagship product, RevDx™, provides complete blood count results. EFA's technology is aimed at enabling rapid diagnostics and supporting telemedicine applications. It was founded in 2016 and is based in Caesarea, Israel.
Oxford Immune Algorithmics is a start-up focused on applying Artificial General Intelligence within the healthcare sector. The company provides AGI-driven solutions that support remote and digital endpoints in healthcare, aimed at understanding health dynamics and managing predictive care. Their primary product, Algocyte, is a diagnostics platform that provides risk assessment scores and health monitoring. It was founded in 2018 and is based in Reading, England.
Loading...